^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

RB1 deletion

i
Other names: RB1, Retinoblastoma 1, RB Transcriptional Corepressor 1, Protein Phosphatase 1, Regulatory Subunit 130, Prepro-Retinoblastoma-Associated Protein, Retinoblastoma-Associated Protein, Retinoblastoma-Associated Protein, Retinoblastoma Suspectibility Protein
Entrez ID:
Related biomarkers:
18d
Myxoid Pleomorphic Liposarcoma: A Review and Update. (PubMed, Cancer Genomics Proteomics)
This review provides information about the clinicoradiological features, pathogenesis, histopathology, and management currently available for MPLPS. In addition, we discuss the differential diagnosis of this novel entity.
Review • Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CD34 (CD34 molecule) • DDIT3 (DNA-damage-inducible transcript 3)
|
TP53 mutation • RB1 deletion
28d
The Role of RB1 and Secondary Genomic Changes in the Development of Spindle Cell and Pleomorphic Lipomas. (PubMed, Genes Chromosomes Cancer)
Thus, at the molecular level, SCL is different from PL/atypical SCLPL. Furthermore, the finding of the same copy number changes (loss of 13q, 6q, 16q, and 17p) in some pleomorphic liposarcomas raises the possibility that a subset of SCLPL/atypical SCLPL have the potential for malignant transformation.
Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)
|
RB1 deletion
1m
The molecular cartography of malignant and benign sebaceous tumours. (PubMed, Nat Commun)
The most frequently mutated gene is NOTCH1. Extensive fusion gene, expression and molecular cluster analyses provide a molecular portrait of this rare and enigmatic tumour type.
Journal • Tumor mutational burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • POLE (DNA Polymerase Epsilon) • POLD1 (DNA Polymerase Delta 1) • HRNR (Hornerin)
|
TP53 mutation • TMB-H • MSI-H/dMMR • POLE mutation • RB1 deletion • RB1 mutation • POLD1 mutation
2ms
Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI-resistant lung cancer. (PubMed, Lung Cancer)
Spatially distinct and simultaneous resistance mechanisms, namely, EGFR L718V mutation and SCLC transformation, contributed to osimertinib resistance. The detection of RB1 2.4 kb small deletion in RB1 gene highlights the importance of deep genomic profiling. Multi-site biopsy and molecular diagnostics are necessary to guide treatment decisions in EGFR-TKI-resistant NSCLC.
Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)
|
TP53 mutation • EGFR mutation • EGFR L858R • EGFR expression • RB1 deletion
|
Tagrisso (osimertinib) • Gilotrif (afatinib)
2ms
Establishment and characterization of a novel cell line ICH-BCPALL-3 from B cell precursor acute lymphoblastic leukemia with TCF3::HLF. (PubMed, Hum Cell)
The cytotoxicity assay indicated that the cell line is sensitive to Aurora Kinase B inhibitor, but not to BCL2 inhibitor. This cell line is the first TCF3::HLF-positive BCP-ALL model without the t(17;19) translocation, facilitating research into leukemogenesis and the development of novel treatments for patients with poor prognosis associated with TCF3::HLF-positive BCP-ALL.
Preclinical • Journal • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • TCF3 (Transcription Factor 3) • NCOR1 (Nuclear Receptor Corepressor 1) • AURKB (Aurora Kinase B) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • ARID5B (AT-Rich Interaction Domain 5B)
|
CDKN2A deletion • RB1 deletion
2ms
A Case of Rare Adipocytic Tumor of the Tongue: Lipoblastoma-Like Tumor With RB1 Gene Deletion. (PubMed, Cureus)
This case highlights the diagnostic challenges of differentiating LLTs from spindle cell lipomas (SCLs), particularly in the context of pRB deficiency and RB1 deletion. This case exemplifies the molecular heterogeneity of neoplasms with lipoblastoma-like features.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • CD34 (CD34 molecule) • DDIT3 (DNA-damage-inducible transcript 3) • PLAG1 (PLAG1 Zinc Finger)
|
RB1 deletion
3ms
Potential Loss of Imprinting of Tumor Suppressor Gene RB1 in Triple Negative Breast Cancer. (PubMed, Breast Cancer Res)
RB1 exhibits potential LOI in TNBCs, laying the groundwork for more precise subtyping and treatment of TNBC patients.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • CDK4 (Cyclin-dependent kinase 4)
|
RB1 deletion
3ms
A rare case of cellular angiofibroma with sarcomatous transformation occurred in the popliteal fossa. (PubMed, Discov Oncol)
This report highlights a rare and extraordinary case of CAS identified in the popliteal fossa. Through NGS, we had identified concurrent deletions of the RB1 and TP53 genes. Although the prognosis of this case was slightly worse than that reported in the literature, it provides additional evidence for expanding the known anatomical range of CAF.
Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)
|
RB1 deletion
3ms
Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. (PubMed, Iran J Pathol)
Extensive testing, including a bone marrow (BM) smear and biopsy, revealed numerous abnormal or blastic cells. Furthermore, flow cytometric analysis of the BM confirmed the presence of plasmacytoid dendritic cell-neoplastic precursor cells exhibiting CD4+ and CD56+ characteristics.
Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CDKN1B (Cyclin dependent kinase inhibitor 1B)
|
RB1 deletion
4ms
Uterine leiomyosarcoma progression: A study of serial recurrences. (PubMed, Gynecol Oncol)
Primary uLMS and subsequent recurrences display genomic intra-individual concordance, with sustained driver cancer gene alterations over time. Chromosomal instability was higher in recurrent tumors.
Journal • BRCA Biomarker
|
ER (Estrogen receptor) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler)
|
TP53 mutation • PTEN mutation • RB1 deletion • ESR1 mutation
4ms
Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers. (PubMed, Cancer Imaging)
Integrating these technologies into personalized treatment plans and the broader framework of precision medicine allows for an in-depth exploration of the relationship between specific biomarkers and disease pathogenesis. This review summarizes the current research on radiomics, genomics, and biomarkers in PCa, and discusses their future potential and applications in advancing individualized patient care.
Review • Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ERG (ETS Transcription Factor ERG) • TMPRSS2 (Transmembrane serine protease 2) • PCA3 (Prostate cancer associated 3)
|
TP53 mutation • PTEN mutation • RB1 deletion
5ms
Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. (PubMed, Int J Gynecol Cancer)
Palbociclib demonstrated only modest clinical activity in unselected patients with ovarian cancer. However, cyclin-dependent kinases 4/6 inhibition showed promising clinical activity in low-grade serous ovarian cancer, warranting further study in this subtype. Further biomarker analyses may facilitate patient selection in high-grade serous ovarian cancer.
P2 data • Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • MUC16 (Mucin 16, Cell Surface Associated)
|
HR positive • CDKN2A deletion • RB1 deletion
|
Ibrance (palbociclib)